Loading...
•
Dec 31, 2022
Eton Q4 2022 Earnings Report
Eton Pharmaceuticals reported fourth quarter results, marked by revenue growth and strategic advancements.
Key Takeaways
Eton Pharmaceuticals reported a strong fourth quarter, marked by a 220% increase in product sales and royalty revenue compared to the prior year, driven by ALKINDI SPRINKLE and Carglumic Acid. The company is optimistic about future growth, expecting to at least double product sales and royalty revenue in 2023.
Reported eighth consecutive quarter of sequential growth in product sales and royalty revenue.
Experienced a 220% increase in product sales and royalty revenue compared to the prior year, reaching $3.5 million.
Expanded rare disease sales force to enhance product promotion and market penetration.
Continued to see increased adoption of Carglumic Acid and ALKINDI SPRINKLE.
Eton
Eton
Forward Guidance
Eton Pharmaceuticals anticipates continued strong growth in 2023, expecting to at least double product sales and royalty revenue. Key growth drivers include ALKINDI SPRINKLE, Carglumic Acid, and the planned launches of Betaine and dehydrated alcohol injection.
Positive Outlook
- Continued momentum of ALKINDI SPRINKLE and Carglumic Acid.
- Completed sales force expansion to accelerate growth.
- Planned launch of Betaine in the coming weeks.
- Anticipated launch of dehydrated alcohol injection later in the year.
- Strong interest in Betaine from patients, prescribers, and advocacy groups.
Challenges Ahead
- Fourth quarter 2022 product sales were negatively impacted by a slowdown in new patient adds during the holiday season.
- Timing of ALKINDI SPRINKLE® product orders from the Company’s specialty pharmacy customer affected sales.
- Risks associated with the process of discovering, developing and commercializing drugs.
- Uncertainties related to regulatory filings and approvals.
- Potential delays in product launches.